Several brokerages have updated their recommendations and price targets on shares of Pulse Biosciences (NASDAQ: PLSE) in the last few weeks:
- 11/17/2026 – Pulse Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $64.00 price target on the stock.
- 11/7/2026 – Pulse Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
- 11/6/2026 – Pulse Biosciences was given a new $65.00 price target by Mizuho.
- 11/6/2026 – Pulse Biosciences had its price target raised by Canaccord Genuity Group from $58.00 to $74.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Pulse Biosciences had its price target raised by Needham & Company LLC from $58.00 to $64.00. They now have a “buy” rating on the stock.
- 10/15/2026 – Pulse Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/13/2026 – Pulse Biosciences was given a new $55.00 price target by Mizuho.
- 10/13/2026 – Pulse Biosciences had its price target raised by Oppenheimer from $35.00 to $60.00. They now have an “outperform” rating on the stock.
- 10/6/2026 – Pulse Biosciences had its price target raised by Canaccord Genuity Group from $43.00 to $58.00. They now have a “buy” rating on the stock.
- 9/23/2026 – Pulse Biosciences is now covered by BTIG Research. They set a “buy” rating and a $70.00 price target on the stock.
- 9/23/2026 – Pulse Biosciences is now covered by BTIG Research. They set a “buy” rating and a $70.00 price target on the stock.
Pulse Biosciences Stock Up 2.2%
NASDAQ PLSE traded up $0.99 during trading hours on Wednesday, hitting $45.83. 331,733 shares of the company were exchanged, compared to its average volume of 393,909. The company has a 50 day moving average of $51.64 and a two-hundred day moving average of $33.60. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $58.94. The firm has a market cap of $3.37 billion, a price-to-earnings ratio of -37.88 and a beta of 1.65.
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.52 million. Pulse Biosciences had a negative return on equity of 77.88% and a negative net margin of 5,603.88%. The business’s quarterly revenue was down 54.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.29) earnings per share. On average, equities research analysts predict that Pulse Biosciences, Inc will post -1.34 EPS for the current year.
Insider Buying and Selling
In other news, COO Liane Teplitsky purchased 1,036 shares of the stock in a transaction on Wednesday, August 26th. The stock was bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at approximately $49,966.28. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have purchased 4,095 shares of company stock worth $199,931. Insiders own 74.00% of the company’s stock.
Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.
Read More
- Five stocks we like better than Pulse Biosciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
